Nick Arab, Pattern Bioscience CEO

Pat­tern Bio­science rais­es $28.7M Se­ries C for faster, more ef­fi­cient an­tibi­ot­ic re­sis­tance test

The team at Pat­tern Bio­science is work­ing on a test that can di­ag­nose drug-re­sis­tant bac­te­r­i­al in­fec­tions and iden­ti­fy ef­fec­tive an­tibi­otics with­in hours, far faster than …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.